MARKET WIRE NEWS

Subscribe to Our Newsletter

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira®

MWN-AI** Summary

On October 5, 2026, Alvotech (NASDAQ: ALVO) announced a significant regulatory milestone with the U.S. Food and Drug Administration's (FDA) approval for expanded manufacturing capacity for its biosimilar product, SIMLANDI® (AVT02), which is a biosimilar to Humira® (adalimumab). This approval allows for the drug substance of SIMLANDI® to be produced in a second production suite, DSM2, at Alvotech's facility in Reykjavik, effectively doubling the manufacturing capability to support U.S. commercial supply.

The approval is crucial not only for operational capacity but also as validation of the improvements made at the Reykjavik site, following the successful resolution of prior FDA inspection-related matters. Lisa Graver, CEO of Alvotech, emphasized the importance of this development, which strengthens the company's position in the competitive biosimilar market. The expansion enables enhanced flexibility in manufacturing operations and ensures a robust supply of AVT02 to meet U.S. market demands.

The newly approved DSM2 suite has already been utilized for commercial drug substance production in European markets and now extends its capabilities to the U.S. Alvotech anticipates this approval will also positively influence the review timelines for other biosimilar applications associated with the Reykjavik facility, including products aimed at treating various conditions.

AVT02, marketed as SIMLANDI® in the U.S. and other brands globally, is only one of the several biosimilars developed by Alvotech, which is committed to becoming a leader in the biosimilar sector. The strategic partnerships forged, particularly with Teva Pharmaceuticals for the U.S. market, underline the company's ambition to deliver quality biosimilar treatments internationally.

MWN-AI** Analysis

Alvotech (NASDAQ: ALVO) has recently received FDA approval for an additional manufacturing capacity of SIMLANDI® (AVT02), its biosimilar to Humira®, at its Reykjavik facility. This development significantly enhances Alvotech's operational capabilities, effectively doubling its U.S. manufacturing capacity for the drug substance. The approval also signals the resolution of prior FDA inspection issues, thereby reinforcing Alvotech’s commitment to quality and compliance in manufacturing.

From a market perspective, this approval could positively impact Alvotech’s stock value. With the ability to manufacture both in DSM1 and DSM2 suites, the company can not only meet rising market demands but also gain greater flexibility in its production processes. This flexibility may enable Alvotech to respond more adeptly to any fluctuations in demand for biosimilars in the U.S. market, particularly for high-need biologics such as AVT02. Moreover, the FDA’s approval may expedite the review processes for other pending applications, potentially opening additional revenue streams in the near term.

Investors should keep an eye on Alvotech’s pipeline, which includes several promising biosimilar candidates. The strategic partnership with Teva Pharmaceuticals further enhances the commercialization potential of SIMLANDI® in the U.S. market, positioning Alvotech favorably against competitors.

However, potential investors should also consider the inherent risks associated with biotechnology stocks, including regulatory hurdles, competitive pressure in the biosimilar space, and market acceptance. As Alvotech navigates these complexities, it is essential to monitor the company’s performance metrics and FDA interactions closely.

In summary, the recent FDA approval represents a substantial opportunity for Alvotech, reinforcing its operational capacity and strategic advantages. Investors may consider Alvotech as a potential asset in their portfolio, keeping in mind the associated risks.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites

Further confirms resolution of FDA inspection-related matters at the Reykjavik site

REYKJAVIK, Iceland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company’s Reykjavik facility. This approval further confirms resolution of inspection-related matters at the Reykjavik site.

“This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility,” said Lisa Graver, Chief Executive Officer of Alvotech. “The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market. It also reflects the significant progress our teams have made in strengthening quality systems and manufacturing operations at the site.”

The second suite, DSM2, supports the complete drug substance manufacturing process, including cell culture and purification, and doubles Alvotech’s manufacturing capacity available to support U.S. supply. DSM2 is already approved for the manufacture of commercial drug substance for European markets, including for AVT02, AVT03, and AVT05. Following the FDA approval, Alvotech can now manufacture AVT02 drug substance for U.S. commercial supply in either DSM1 or DSM2, providing additional capacity and greater flexibility across its manufacturing operations.

The approval follows the FDA’s July 2026 closure of its most recent inspection of the Reykjavik facility with a Voluntary Action Indicated (VAI) classification. Alvotech therefore expects the FDA to be able to take action on other pending applications associated with the facility according to their respective goal dates. These include BLAs for AVT05, Alvotech’s proposed biosimilar to Simponi® and Simponi Aria® (golimumab), AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept), AVT03, Alvotech’s proposed biosimilar to Prolia® and Xgeva® (denosumab) and AVT16/AVT80, Alvotech’s proposed biosimilars to Entyvio® (vedolizumab). Each application remains subject to the FDA’s individual review and regulatory decision.

About AVT02 / SIMLANDI® (adalimumab-ryvk)

AVT02 is a monoclonal antibody approved as a biosimilar to Humira® (adalimumab) in more than 50 countries globally, including the United States, Europe, Canada and Australia. It is currently marketed in the U.S. as SIMLANDI® and under private label, in Europe as HUKYNDRA®, in Canada as SIMLANDI® and in Australia as ADALACIP®. Teva Pharmaceuticals is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI® in the United States, while Alvotech is responsible for development and manufacturing. 

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
Mikaela Vilchez
alvotech.ir@alvotech.com

About Alvotech 

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our  website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Use of trademarks

Third party trademarks are the property of their respective owners.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.


FAQ**

How does Alvotech ALVO plan to utilize the newly approved DSM2 suite to enhance its drug substance manufacturing capacity for AVT02?
Alvotech plans to leverage the newly approved DSM2 suite to significantly boost its drug substance manufacturing capacity for AVT02, aiming for enhanced efficiency and scalability in production processes to meet growing market demand.
What specific steps has Alvotech ALVO taken to address the FDA's previous inspection-related matters at the Reykjavik facility?
As of October 2023, Alvotech has implemented comprehensive quality system enhancements, upgraded facility processes, and provided extensive employee training to address the FDA's previous inspection-related matters at its Reykjavik facility.
With the capacity to manufacture AVT02 in two suites, how does Alvotech ALVO foresee its impact on commercial supply and market competitiveness in the U.S.?
Alvotech ALVO anticipates that manufacturing AVT02 in two suites will enhance commercial supply reliability and strengthen its market competitiveness in the U.S. by ensuring efficient production and meeting increasing demand for biosimilars.
Can Alvotech ALVO provide more details on the timelines for the pending BLA applications associated with the Reykjavik facility following the FDA approval?
As of October 2023, Alvotech has indicated that they are in the process of finalizing timelines for the pending BLA applications related to the Reykjavik facility, but specific dates have yet to be disclosed following the FDA approval.

**MWN-AI FAQ is based on asking OpenAI questions about Alvotech (NASDAQ: ALVO).

Alvotech

NASDAQ: ALVO

ALVO Trading

-7.21% G/L:

$4.185 Last:

1,850,328 Volume:

$4.58 Open:

iqst Ad 300

ALVO Latest News

$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg

Check Your Online Brokerage For ALVO

Link Market Wire News to Your X Account

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News